UK markets close in 7 hours 50 minutes

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.40-0.60 (-6.00%)
At close: 04:00PM EDT
9.56 +0.16 (+1.70%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.00
Open10.00
Bid9.35 x 400
Ask9.46 x 100
Day's range9.37 - 10.17
52-week range3.96 - 12.45
Volume173,152
Avg. volume376,988
Market cap942.876M
Beta (5Y monthly)1.38
PE ratio (TTM)N/A
EPS (TTM)-1.57
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.60
  • Globe Newswire

    Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

    BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be app

  • Globe Newswire

    Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

    BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day o

  • GlobeNewswire

    Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

    BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered, highly